SOHO Annual Meeting

Tweets from Society of Hematologic Oncology

Latest from Society of Hematologic Oncology

Real-World Data Show Tisagenlecleucel is an Effective Treatment for DLBCL

September 15, 2019

In a prospective postmarketing assessment, the use of tisagenlecleucel for treatment of adult patients with diffuse large B-cell lymphoma, lead to responses that were similar to studies of children and adolescents with B-cell acute lymphoblastic leukemia.

More Research and Development on JAK Inhibition May Improve Myelofibrosis Management

September 15, 2019

In an interview with Targeted Oncology during the 2019 SOHO Annual Meeting, Laura C. Michaelis, MD, discussed the currently approved JAK inhibitors and the future landscape for myelofibrosis, as well as treatment considerations for graft-versus-host disease.

Safety Profiles of Ruxolitinib and Fedratinib in Myelofibrosis

September 14, 2019

Prithviraj Bose, MD, discusses differences in the safety profiles of ruxolitinib and fedratinib in the treatment of myelofibrosis.

Phase II JULIET Study Continues To Show Benefit of Tisagenlecleucel in DLBCL

September 14, 2019

Recent updates to the JULIET study, presented at the 2019 SOHO Annual Meeting, show that tisagenlecleucel has sustained benefit throughout the course of the trial with high response rates, and long duration in adults with relapsed/refractory diffuse large B-cell lymphoma.

Improvement in PFS Shown With Checkpoint Inhibition Before Transplantation in R/R Hodgkin Lymphoma

September 13, 2019

In a retrospective study of patients with replaced or refractory Hodgkin lymphoma, checkpoint inhibition prior to haploidentical stem cell transplantation improved progression-free survival and risk for relapse, based on results presented at the 2019 SOHO Annual Meeting.

Fedratinib Approval Further Validates JAK Inhibition for Myelofibrosis Treatment

September 13, 2019

In an interview with Targeted Oncology during the 2019 SOHO Annual Meeting, Ruben Mesa, MD, discussed the JAKARTA and JAKARTA-2 studies and the implications their data have on the field of myelofibrosis.